2,271 press releases in English indexed under biotech & pharma.
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
EMERYVILLE, Calif., Sept. 28, 2026 -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.
Route 92 Medical announces U.S. FDA clearance for the FreeClimb 46 Catheter with Tenzing 4.
Initial data expected in the first half of 2027 Initial data expected in the first half of 2027
DURHAM, N.C., Sept. 28, 2026 -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships
Government funding, hardware advances and software ecosystems are accelerating quantum adoption in cybersecurity, finance, drug discovery, manufacturing and logistics Government funding, hardware advances and software ecosystems are accelerating quantum adoption in cybersecurity, finance, drug discovery, manufacturing and logistics
Boost ROI with validated antibodies, standardized workflows, multiplex digital pathology, governed AI, regional support and reliable supply Boost ROI with validated antibodies, standardized workflows, multiplex digital pathology, governed AI, regional support and reliable supply
Improve ROI via validated target selection, parallel optimization, early assays, regulatory planning, AI governance, and laboratory, clinical and manufacturing partnerships Improve ROI via validated target selection, parallel optimization, early assays, regulatory planning, AI governance, and laboratory, clinical and manufacturing partnerships
Boost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent Boost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent
Maximize ROI through quality data, standardized assays, closed-loop lab integration, uncertainty-led testing, cross-functional governance and secure partnerships Maximize ROI through quality data, standardized assays, closed-loop lab integration, uncertainty-led testing, cross-functional governance and secure partnerships
Boost ROI with AI-assisted discovery, rigorous validation, early stability and delivery testing, quality controls, regional partnerships, and fit-for-purpose regulatory plans Boost ROI with AI-assisted discovery, rigorous validation, early stability and delivery testing, quality controls, regional partnerships, and fit-for-purpose regulatory plans